



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Poster: CLL-105

Cumulative Incidence of Grade 3 or Higher Infections in Patients With CLL/SLL Treated With BTKi-Based Regimens

Stephanos Vassilopoulos MD¹, Quynh-Lam Tran BS¹, Markos Kalligeros MD¹, Fadi Shehadeh MSc^{1,2}, Eleftherios Mylonakis MD, PhD¹

¹Infectious Diseases Division, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, USA. ²School of Electrical and Computer Engineering, National Technical University of Athens, Athens, Greece

Poster: CLL-140

Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL

Emily Bryer DO¹, Shira Paul MD², Jonathan Chen BS¹, Christopher Pleyer MD¹, Adrian Wiestner MD¹, Clare Sun MD¹

¹NIH, Bethesda, USA. ²Uniformed Services University of the Health Sciences, Bethesda, USA

Poster: CLL-152

The Significance of Rai and Binet Clinical Staging on the Survival of CLL Patients in the Kurdistan Region of Iraq

Shlan Mohammed M.B.Ch.B FKBMS¹, Ahmed Yassin MBChB DM CAB F.I.C.M.S², Rawand Shamoon MBChB MS PhD²

¹Nanakaly Hospital, Erbil, Iraq. ²College of Medicine Hawler Medical University, Erbil, Iraq

Poster: CLL-162

PTX3 is Constitutively Active in CLL Cells

Uri Rozovski MD^{1,2,3}, Ivo Veletik MD³, David Harris MA³, Ping Li PhD³, Zhiming Liu BA³, Preetesh Jain MD³, Taghi Manshouri MA³, Alessandra Ferrajoli MD³, Jan Burger MD³, Prithviraj Bose MD³, Phillip Thompson MD³, Nitin Jain MD³, William Wierda MD³, Srdan Verstovsek MD³, Michael Keating MD³, Zeev Estrov MD³

¹Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. ²Davidoff Cancer Center, Beilinson Campus, Tel Aviv, Israel. ³Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA

Poster: CLL-177

Elevated Serum ELABELA and SERPINA3 as Novel Biomarkers to Predict Poor Prognosis in Egyptian Chronic Lymphocytic Leukemia Patients

Amira Othman MS¹, Noha Abdel-Rahman MD¹, May Denewer MD², Laila Eissa MD¹

¹Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. ²Clinical Hematology Unit, Internal Medicine Department, Oncology Center, Mansoura University, Mansoura, Egypt, Mansoura, Egypt

Poster: CLL-189

Ibrutinib Treatment and Its Impact on Circulating Immune Cells in Chronic Lymphocytic Leukemia Patients

Francesca Morelli MD¹, Chiara Maria Rapolla MD¹, Alessandro Sanna MD²

¹Hematology Department University of Florence, Florence, Italy. ²Haematology, Department of Oncology, AOU Careggi, Florence, Italy

Poster: CLL-211

Humoral Immune Response Following COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia (CLL) and Indolent Non-Hodgkin Lymphoma (NHL): Results From a Large, Single-Center Observational Study

Frédérique St-Pierre MD, CM, Peter Doukas MD, Jennifer Boyer APRN, MSN, Mariana Nieves RN, BSN, Shuo Ma MD, PhD

Northwestern University, Chicago, USA

Poster: CLL-217

Patient Characteristics and Time to Next Treatment With Ibrutinib and Anti-CD20 Monotherapy as First-Line Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Xiaoxiao Lu MD, PhD, MPH¹, Jinghua He PhD², Tao Ran PhD², Linda Wu PhD¹, Sumeet Panjabi PhD², Julie M Vose MD, MBA³

¹Janssen Scientific Affairs, Horsham, USA. ²Janssen Scientific Affairs, Titusville, USA. ³University of Nebraska Medical Center, Omaha, USA

Poster: CLL-224

Coronavirus Disease Mortality and Outcome in Macedonian Patients With Chronic Lymphocytic Leukemia: Single-Center Experience

Sanja Trajkova PhD, Aleksandra Pivkova Veljanovska MD, PhD, Marija Popova Labacevska MD, Nevenka Ridova MD, Simona Stojanovska MD, Dushko Dukovski MD, Irina Panovska Stavridis PhD

University Clinic for Hematology, Skopje, the former Yugoslav Republic of Macedonia
